skip to main content
Close Icon We use cookies to improve your website experience.  To learn about our use of cookies and how you can manage your cookie settings, please see our Cookie Policy.  By continuing to use the website, you consent to our use of cookies.
Informa pharma logo

Pharma Intelligence is part of the Informa Intelligence Division of Informa PLC

This is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Pharma Intelligence Logo
Search Icon Pharma Report StoreRecommendationsProduct loginProductLogin
Global Search Configuration

Refine Results

Clear All

Specialism

Show More

Resources

Show More

Show More

Products

Show More

Show More

46 Total results for product and free and sample content found

Generics Bulletin

Coherus Is Confident After US Ranibizumab Filing

Coherus_Is_Confident_After_US

Having seen its development partner Bioeq file with the FDA in December last year, Coherus is confident that it will be a leader in the US biosimilar ranibizumab market targeting Lucentis.

Topic Biosimilars Deals

View opinion

Scrip

Stockwatch: The First Coronavirus Earnings Season May Come Early

The impact of the coronavirus pandemic on investors’ portfolios was immediately apparent at the end of the first quarter of 2020. Equity market sell-offs are reflections of investors’ concern for future financial performance which, if material, may have to be announced early.

Topic Coronavirus

View opinion

Scrip

Stockwatch: Earnings Season Catches An Early Cold As Coronavirus Sweeps In

Stockwatch_Earnings_Season_Catches_An_Early_Cold

As industry bellwether J&J kicked-off 2019 fourth-quarter and full-year earnings season for life sciences companies, its financial results left investors feeling the cold. But with coronavirus envy sweeping a raft of smaller biotech companies, J&J may have the last laugh.

View opinion

Datamonitor Healthcare

Alnylam and partner Sanofi deliver on their RNAi promise with groundbreaking results in rare polyneuropathy condition

Alnylam’s high stakes investment in RNAi therapeutics delivers a major short-term win for stakeholders, but long-term commercial success is still in question.

Topic BioPharmaceutical

View opinion

Datamonitor Healthcare

Allergan uses Native American tribe’s sovereign immunity to delay generic entry

Allergan’s deal with the Saint Regis Mohawk Tribe will shore up revenue from its top-selling dry eye drug Restasis in the short term.

Topic Company analysis

View opinion

Datamonitor Healthcare

Gilead expands into CAR-T therapy with $11.9bn purchase of Kite Pharmaceuticals

Pharmavitae Analytics expects Gilead’s purchase of Kite to generate long-term growth for Gilead.

Topic Company analysis

View opinion

Datamonitor Healthcare

Xtandi will have first-mover advantage in non-metastatic prostate cancer setting

Positive results from the Phase III PROSPER trial (ClinicalTrials.gov identifier

Topic Cancer

View opinion

Datamonitor Healthcare

Ocrevus FDA approval marks watershed moment for MS market

Roche’s exciting new multiple sclerosis (MS) drug Ocrevus (ocrelizumab) was approved by the US Food and Drug Administration (FDA) on 29 March 2017 (Roche, 2017). The drug is indicated for relapsing-remitting MS (RRMS) on the strength of the two OPERA studies, which showed clear superiority over the current standard of care, Rebif (interferon beta-1a; Merck KGaA/Pfizer).

Topic FDA Multiple Sclerosis

View opinion

Datamonitor Healthcare

Disappointing Translarna failure is an isolated event for CF pipeline

PTC Therapeutics announced the failure of its ACT CF trial of Translarna (ataluren) in nonsense mutation cystic fibrosis (nmCF) patients, bringing a halt to any further planned developmental activities in the indication. Although there was a slight treatment effect, Translarna failed to significantly improve pulmonary measures compared to placebo.

Topic Comment wire

View opinion
Show More

Next steps

Getting a demo tailored to your needs is the best way to see how our solutions will help you gain an advantage.

Request live demo now:

Request a free demo

Our team is always happy to hear from you. Please call us at:

  • US Toll-Free  : +1 888 670 8900
  • US Toll           : +1 908 547 2200
  • UK & Europe : +44 (20) 337 73737
  • Australia        : +61 2 8705 6907
  • Japan              : +81 3 6273 4260

Or please submit your inquiry via the form so that we can provide you the best possible customer service.
Contact Customer Services

Have an immediate and specific information need?

Browse and buy from 1000s of analysis and research reports now:

Shop now